Chronic Kidney Disease Requiring Chronic Dialysis Clinical Trial
Official title:
Cost-effectiveness of Urgent-start Therapies Hemodialysis and Peritoneal Dialysis
This study will evaluate the cost-effectiveness of unplanned dialysis (peritoneal dialysis and hemodialysis) in chronic kidney disease (CKD) during the first year of therapy in a single center.
Despite evidence of worse outcomes, initiation of renal replacement therapy by unplanned
modalities in chronic kidney disease (CKD) patients is the reality in the practice for both
hemodialysis and peritoneal dialysis. Unplanned therapy peritoneal dialysis (PD) is the
initiation of the modality in less than 48 hours after implantation of the peritoneal
catheter, without family training or adequacy of the home. Unplanned hemodialysis (HD) is the
initiation of the method without a functional arteriovenous fistula, i.e., with a central
venous catheter (nontunneled or tunneled).
Growing evidence shows unplanned PD (or urgent start PD) as a viable and safe alternative to
unplanned HD, with the similar rates of infection and survival.
On planned scenario, solid studies demonstrate that PD has a better cost-effectiveness when
compared to HD, however the literature lacks in this kind of analysis in unplanned methods.
Briefly, the workgroup will follow patients that would anyway start a Renal Replacement
Therapy by an unplanned method and register Government payment for the therapy, including the
therapy direct costs and the costs with events (internation, infection), access for dialysis,
laboratory and CKD specific medications to performed a cost-effectiveness analysis in both
groups (Unplanned Hemodialysis and Unplanned Peritoneal Dialysis).
The workgroup is responsible for the placement of the catheters (PD and HD) using the
Seldinger Technique.
The study is unicentric, the therapy is continuous and necessary for the maintenance of life;
therefore, no great difficult in the follow up is expected. A database with up-to-date
information of patients will be functional during the study.
A Markov model will be developed to assess the relative cost-effectiveness of different
dialysis modality distribution scenarios versus current practice. The model considers a
hypothetical adult incident patient cohort with end-stage renal disease (ESRD) requiring
dialysis and adopts payer perspective. Markov models have been used to model dialysis
treatment in previous economic analyses and are widely accepted to be suitable for modelling
chronic condition
Statistical analysis plan:
From the study protocol, the data will be entered in a spreadsheet and verified typographical
errors and their analysis will be performed using the statistical program Statistical
Analysis System (SAS) for Windows (version 9.2: SAS Institute, Cary, North Carolina, USA,
2012).
Considering an alpha error of 0.05 and a beta error of 0.2, power of statistic test of 0.8
and cost difference detection between groups of 15%, the calculated sample size for each
group is 94 patients.
Initially descriptive analysis will be done for all patients treated in the period,
calculated measures of central tendency and dispersion for continuous variables and
frequencies for categorical variables.
For the analysis of repeated measures, asymmetric distribution (gamma) under the Generalized
Linear Model (GENMOD) procedure will be used.
Chi Square will be used to compare categorical variable between the two groups. T test or
Mann-Whitney will be used to compare parametric continue variables.
By the utilization of Kaplan Meyer and log rank, survival curves of the two groups will be
presented at the end of the study. A p-value of 5% or lower will be considered to be
statistically significant
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05700851 -
Immuno-nutrition Supplementation in Haemodialysis
|
N/A | |
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Completed |
NCT01464190 -
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
|
Phase 3 | |
Recruiting |
NCT06040281 -
Smart and Fit for Kidney Transplantation
|
N/A | |
Active, not recruiting |
NCT03535922 -
Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care
|
N/A | |
Completed |
NCT04622709 -
Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis
|
Phase 2 | |
Completed |
NCT04585607 -
Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia
|
Phase 4 | |
Completed |
NCT03182699 -
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT03942744 -
The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.
|
N/A | |
Completed |
NCT04549597 -
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
|
Phase 4 | |
Recruiting |
NCT04659525 -
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
|
Phase 4 | |
Completed |
NCT04125537 -
Pathways Project: Kidney Supportive Care
|
||
Recruiting |
NCT03347773 -
Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity
|
N/A | |
Recruiting |
NCT04397653 -
Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
|
Phase 4 | |
Active, not recruiting |
NCT03938285 -
Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal
|
N/A | |
Completed |
NCT03525223 -
Modulation of Tissue Sodium in Hemodialysis Patients
|
N/A | |
Completed |
NCT01324128 -
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
|
Phase 3 | |
Not yet recruiting |
NCT04600193 -
a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT06225544 -
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
|
Phase 2 | |
Recruiting |
NCT05209880 -
Advance Care Planning in the Emergency Department
|
N/A |